Clinical trials: Disease-free Survival
Malignant Pleural Mesothelioma
Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
Liposomal doxorubicin consists on doxorubicin encapsulated in liposomes that are composed of phosphatidylcholine and cholesterol.
- Trial name
- NCT00886028
- Testing
- Liposomal doxorubicin, Cisplatin
- Where
- Mexico
- Volunteers
- 31 people
- Sponsor
- National Institute of Cancerología
Relapsed and Refractory Multiple Myeloma (RRMM)
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Primary Objective: 1. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after…
- Trial name
- NCT05673967
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Colorectal Cancer
MOR-1 Expression in Colorectal Cancer and Disease-free Survival Relationship. Five-year Follow-up.
Colorectal cancer (CRC) is a global burden and one of the most frequent types of cancer. Colorectal cancer therapy is complex and surgery remains the cornerstone for its treatment, combined with chemotherapy and radiotherapy.
- Trial name
- MOROCCO (NCT03601351)
- Testing
- ELISA for MOR-1 expression
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Hospital Universitario La Fe
Diffuse Large B Cell Lymphoma
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
The purpose of this study is to evaluate the antitumor efficacy and the safety of MK 2206 in patients with relapsed or refractory diffuse large B cell lymphoma.
- Trial name
- AKTIL (NCT01466868)
- Testing
- MK2206
- Where
- 13 sites in France
- Volunteers
- 22 people
- Sponsor
- Centre Leon Berard